Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR -mutant NSCLC in the US and China.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Shandong University, Qilu Hospital of Shandong University
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: closed
OpenAlex ID: W7162683872
Cites:
Cited by:
Related to: